Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients

Jun Watanabe, Kunihisa Kobayashi, Fumio Umeda, Teruaki Yamauchi, Kazuo Mimura, Naoki Nakashima, Mitsunori Masakado, Shinsuke Hiramatsu, Hajime Nawata

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


In the present study, we examined the levels of plasma lipids and apolipoproteins in patients with non-insulin dependent diabetes mellitus (NIDDM) with hypercholesterolemia in different apolipoprotein E (apo E) phenotypes. We also examined the influences of apo E polymorphism on the response to pravastatin. The patients were divided into three groups, E4/E3, E3/E3, and E3/E2. There were no differences in the baseline levels of plasma lipids and apolipoproteins, except that the level of triglycerides in E3/E2 heterozygotes was significantly higher than E3/E3 homozygotes. Three months of pravastatin administration significantly reduced plasma levels of total cholesterol and low-density lipoprotein cholesterol in each group to the same degree. We observed a significant reduction of apo B both in the E4/E3 and E3/E3 groups and apo E in the E3/E3 group. Such reduction was not observed in the E3/E2 group. We conclude that pravastatin is a potent drug to correct lipid abnormalities, particularly in NIDDM patients with apo E4/E3 and E3/E3. In the E3/E2 group, its effectiveness may be diminished.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalDiabetes Research and Clinical Practice
Issue number1
Publication statusPublished - Apr 1993

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients'. Together they form a unique fingerprint.

Cite this